在分析性治疗中断期间减轻艾滋病毒传播风险的协作性多学科方法。
A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.
作者信息
Peluso Michael J, Dee Lynda, Campbell Danielle, Taylor Jeff, Hoh Rebecca, Rutishauser Rachel L, Sauceda John, Deeks Steven G, Dubé Karine
机构信息
Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
AIDS Action Baltimore, Baltimore, MD, USA.
出版信息
J Virus Erad. 2020 Feb 20;6(1):34-37. doi: 10.1016/S2055-6640(20)30009-1.
Abstract
Analytic treatment interruptions (ATIs) are currently the standard for assessing the impact of experimental interventions aimed at inducing sustained antiretroviral therapy (ART)-free remission in trials related to HIV cure. ATIs are associated with substantial risk to both study participants and their sexual partner(s). Two documented HIV transmissions occurring in the context of ATIs have been recently reported, but recommendations for mitigating the risk of such events during ATIs are limited. We outline a practical approach to risk mitigation during ATI studies and describe strategies we are utilising in an upcoming clinical trial that may be applicable to other centres.
摘要
分析性治疗中断（ATIs）目前是评估旨在诱导持续停止抗逆转录病毒治疗（ART）实现缓解的实验性干预措施在与HIV治愈相关试验中影响的标准方法。ATIs对研究参与者及其性伴侣都存在重大风险。最近有两份记录在案的在ATIs期间发生的HIV传播报告，但关于在ATIs期间降低此类事件风险的建议有限。我们概述了在ATI研究期间降低风险的实用方法，并描述了我们在即将开展的一项临床试验中正在采用的策略，这些策略可能适用于其他中心。
相似文献
1
A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.
J Virus Erad. 2020 Feb 20;6(1):34-37. doi: 10.1016/S2055-6640(20)30009-1.
2
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Cochrane Database Syst Rev. 2011 Jul 6(7):CD003510. doi: 10.1002/14651858.CD003510.pub3.
3
Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.
AIDS Res Hum Retroviruses. 2025 May;41(5):241-252. doi: 10.1089/aid.2024.0086. Epub 2025 Feb 5.
4
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003510. doi: 10.1002/14651858.CD003510.pub2.
5
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Cochrane Database Syst Rev. 2010 Mar 17(3):CD008440. doi: 10.1002/14651858.CD008440.
7
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148.
引用本文的文献
1
The impact of magnitude and duration of plasma viremia during analytical treatment interruptions on CD4 T cell recovery after ART resumption.
J Virus Erad. 2025 Jun 27;11(3):100604. doi: 10.1016/j.jve.2025.100604. eCollection 2025 Sep.
2
Development and Evaluation of Decision Partner: A Decision Aid for HIV Remission Clinical Trial Participation.
AIDS Behav. 2025 Jun 10. doi: 10.1007/s10461-025-04764-1.
3
Combination immunotherapy induces post-intervention control of HIV.
Res Sq. 2025 Mar 19:rs.3.rs-6141479. doi: 10.21203/rs.3.rs-6141479/v1.
4
'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.
HIV Res Clin Pract. 2025 Dec;26(1):2455917. doi: 10.1080/25787489.2025.2455917. Epub 2025 Jan 25.
5
Evaluating the psychosocial experiences of participants in HIV cure research before, during, and after analytical treatment interruptions: A longitudinal qualitative study in the United States.
Soc Sci Med. 2025 Feb;366:117644. doi: 10.1016/j.socscimed.2024.117644. Epub 2024 Dec 25.
6
HIV Clinical Providers' Awareness, Attitudes, and Willingness to Support Patient Outreach Efforts for HIV Cure-Directed Research in Philadelphia, United States.
Open Forum Infect Dis. 2024 Nov 19;11(12):ofae687. doi: 10.1093/ofid/ofae687. eCollection 2024 Dec.
7
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.
J Infect Dis. 2025 Feb 20;231(2):e419-e428. doi: 10.1093/infdis/jiae551.
8
Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.
J Virus Erad. 2024 Sep 11;10(3):100386. doi: 10.1016/j.jve.2024.100386. eCollection 2024 Sep.
9
Recall and Appraisal of the Risks, Benefits, and Objectives of Interrupting HIV Treatment in an HIV Cure-Related Study.
AIDS Behav. 2024 Dec;28(12):4136-4145. doi: 10.1007/s10461-024-04485-x. Epub 2024 Sep 17.
10
"This Is Actually a Really Unique Moment in Time": Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions-A Qualitative Interview Study in the United States.
AIDS Res Hum Retroviruses. 2024 Aug;40(8):455-463. doi: 10.1089/AID.2023.0105. Epub 2024 Mar 27.
本文引用的文献
1
Unintended HIV-1 Infection During Analytical Therapy Interruption.
J Infect Dis. 2020 Apr 27;221(10):1740-1742. doi: 10.1093/infdis/jiz611.
2
How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach.
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S7-S11. doi: 10.1093/infdis/jiz163.
3
How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S24-S26. doi: 10.1093/infdis/jiz222.
4
Human Immunodeficiency Virus Transmission Risk in Analytical Treatment Interruption Studies: Relational Factors and Moral Responsibility.
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S12-S15. doi: 10.1093/infdis/jiz090.
5
Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium.
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S1-S4. doi: 10.1093/infdis/jiz173.
6
Implementation Strategies to Increase PrEP Uptake in the South.
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269. doi: 10.1007/s11904-019-00447-4.
7
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.
8
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15.
9
Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S5-S6. doi: 10.1093/infdis/jiz012.
10
Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.
AIDS. 2019 Feb 1;33(2):279-284. doi: 10.1097/QAD.0000000000002058.
Zotero 插件